Evidence map›Paper›PMID 27888377›Full record

ArticleClinical & experimental metastasis2017

Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China.

Hongwei Li, Jianzhong Cao, Xiaqin Zhang, Xing Song, Weili Wang, Sufang Jia, Zhengran Li, Haixia Jia, Xing Cao, Wei Zhou and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hongwei LiDepartment of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China. 3420010@163.com.
Jianzhong CaoDepartment of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Xiaqin ZhangDepartment of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Xing SongDepartment of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Weili WangDepartment of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Sufang JiaDepartment of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Zhengran LiDepartment of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Haixia JiaDepartment of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Xing CaoDepartment of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Wei ZhouDepartment of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Jianhong LianDepartment of Surgery, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Songye HanDepartment of Chemotherapy, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Weihua YangDepartment of Chemotherapy, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Yanfen XiDepartment of Pathology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Shenming LianDepartment of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China.
Haoxing JingDepartment of Pathology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, 030013, Shanxi, People's Republic of China. jinhongxing1960@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study aimed to explore the correlations between status of epidermal growth factor receptor (EGFR) mutations and distant metastases. A total of 1063 patients with lung adenocarcinoma indentified with status of EGFR mutations from August 2010 to May 2015 at Shanxi Cancer Hospital were enrolled. 456 patients were confirmed with EGFR mutations. The associations among EGFR mutations, clinical factors, and distant metastases at initial diagnosis were evaluated. Patients harboring EGFR mutation were more likely to be female (P < 0.001), with no smoking history (P < 0.001), brain metastases (P = 0.029), and higher ECOG performance scores (P = 0.025). The correlation between EGFR mutation status and distant metastases showed statistical significance both in univariate (P = 0.022) and in multivariate analysis (OR 1.573, 95 % CI 1.202-2.059, P = 0.001) especially in brain metastases (OR 1.675, 95 % CI 1.132-2.479, P = 0.010) and lung metastases (OR 1.571, 59 % CI 1.101-2.243 P = 0.013). Furthermore, the 19del mutations showed associations with brain metastases (OR 1.586, 95 % CI 1.028-2.447, P = 0.037), and lung metastases (OR 1.587, 95 % CI 1.065-2.346, P = 0.023). The exon 21 point mutations showed statistically significant differences in liver metastases (OR 1.987, 95 % CI 1.094-3.067, P = 0.024). In conclusion, the EGFR mutations in lung adenocarcinoma patients were independently correlated with distant metastases. Subgroup analyses showed that patients harboring 19del mutations presented different distant metastases compared with those harboring 21 point mutaions.

Indexed as

AdenocarcinomaAdenocarcinoma of LungAdultAgedBrain NeoplasmsChinaErbB ReceptorsFemaleHumansLung NeoplasmsMaleMiddle AgedMutationNeoplasm MetastasisProtein Kinase InhibitorsErbB ReceptorsProtein Kinase InhibitorsDistant metastasesEGFR mutationLung adenocarcinoma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.